Blossom Biosciences Files IPO Prospectus Following $72M Series A Backed by Hansoh Pharma and Cormorant Asset Management

On June 16, Blossom Biosciences, co-founded and incubated by Hansoh Pharmaceutical Group Company Limited (hereinafter referred to as "Hansoh Pharma") and Osprey Asset Management (hereinafter referred to as "Osprey AM"), announced its official establishment. Committed to bringing potentially breakthrough therapeutics to more patients in China, the company has successfully completed a $72 million Series A financing round co-led by Hansoh Pharma and Osprey AM.

Bosheng Pharma has entered into an agreement with Hansoh Pharma, under which Hansoh Pharma will provide preclinical, clinical, and commercialization support to accelerate the R&D and market launch of its product pipeline in China. Osprey Asset Management will support Bosheng Pharma in in-licensing innovative products through its extensive global biopharma resources and portfolio companies. Dr. Andrew Phillips, Managing Director of Osprey Asset Management and former CEO of C4 Therapeutics, Inc., has been appointed as the Acting CEO of Bosheng Pharma.

Founded in 2013, Osprey Capital Management is a renowned life sciences investment firm, with assets under management exceeding US$3 billion as of June 2021. Focusing on fundamental scientific principles, Osprey Capital Management provides financial backing to the most innovative and promising public and private companies in the biotechnology and related industries.

Hansoh Pharma (3692.HK) is a leading biopharmaceutical company in Asia, committed to improving human health through continuous innovation, with over 10,000 employees in China and the United States. Hansoh Pharma's primary operating entity, Hansoh Pharmaceutical, was established in 1995 as an innovative pharmaceutical company integrating R&D, manufacturing, and sales, and holds a leading position in the treatment of major diseases such as oncology, central nervous system disorders, anti-infectives, and diabetes. As of December 2020, the company employed over 1,600 professional R&D personnel, and Hansoh Pharmaceutical has successfully launched four Class 1 new drugs through independent research and development.